Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMIOS phase 3 trial of cenerimod in active lupus nephritis
2025-522984-14-00Phase 3Authorised
- Sponsor
- Viatris
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) and lupus nephritis (LN) comparing Cenerimod plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Complete renal response at Week 76. Planned start Sep 2026; status: authorised.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2025-522984-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522984-14-00.